KR20230162134A - 세포 게놈에서 상동성 지정 수복 (hdr)의 효율을 증가시키는 방법 - Google Patents

세포 게놈에서 상동성 지정 수복 (hdr)의 효율을 증가시키는 방법 Download PDF

Info

Publication number
KR20230162134A
KR20230162134A KR1020237039262A KR20237039262A KR20230162134A KR 20230162134 A KR20230162134 A KR 20230162134A KR 1020237039262 A KR1020237039262 A KR 1020237039262A KR 20237039262 A KR20237039262 A KR 20237039262A KR 20230162134 A KR20230162134 A KR 20230162134A
Authority
KR
South Korea
Prior art keywords
hdr
cells
sequence
dna
nuclease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237039262A
Other languages
English (en)
Korean (ko)
Inventor
존 네이선 페더
치 궈
가브리엘 앨런 민티에
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61006349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20230162134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20230162134A publication Critical patent/KR20230162134A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020237039262A 2016-12-20 2017-12-20 세포 게놈에서 상동성 지정 수복 (hdr)의 효율을 증가시키는 방법 Pending KR20230162134A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662437042P 2016-12-20 2016-12-20
US62/437,042 2016-12-20
KR1020197020845A KR20190095412A (ko) 2016-12-20 2017-12-20 세포 게놈에서 상동성 지정 수복 (hdr)의 효율을 증가시키는 방법
PCT/US2017/067569 WO2018119060A1 (en) 2016-12-20 2017-12-20 Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197020845A Division KR20190095412A (ko) 2016-12-20 2017-12-20 세포 게놈에서 상동성 지정 수복 (hdr)의 효율을 증가시키는 방법

Publications (1)

Publication Number Publication Date
KR20230162134A true KR20230162134A (ko) 2023-11-28

Family

ID=61006349

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237039262A Pending KR20230162134A (ko) 2016-12-20 2017-12-20 세포 게놈에서 상동성 지정 수복 (hdr)의 효율을 증가시키는 방법
KR1020197020845A Ceased KR20190095412A (ko) 2016-12-20 2017-12-20 세포 게놈에서 상동성 지정 수복 (hdr)의 효율을 증가시키는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197020845A Ceased KR20190095412A (ko) 2016-12-20 2017-12-20 세포 게놈에서 상동성 지정 수복 (hdr)의 효율을 증가시키는 방법

Country Status (7)

Country Link
US (1) US20230193321A1 (https=)
EP (2) EP4286523A3 (https=)
JP (3) JP2020510443A (https=)
KR (2) KR20230162134A (https=)
CN (2) CN110300803B (https=)
ES (1) ES2962711T3 (https=)
WO (1) WO2018119060A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
EP3353296B1 (en) 2015-09-24 2020-11-04 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
ES2962711T3 (es) 2016-12-20 2024-03-20 Bristol Myers Squibb Co Métodos para aumentar la eficacia de la reparación dirigida por homología (HDR) en el genoma celular
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
JP2020537515A (ja) * 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Hpv特異的結合分子
WO2020014577A1 (en) * 2018-07-13 2020-01-16 Allele Biotechnology And Pharmaceuticals, Inc. Methods of achieving high specificity of genome editing
CA3144106A1 (en) 2019-07-03 2021-01-07 Integrated Dna Technologies, Inc. Identification, characterization, and quantitation of crispr-introduced double-stranded dna break repairs
CN119193713A (zh) 2019-10-24 2024-12-27 合成Dna技术公司 修饰的双链供体模板
CN111549052A (zh) * 2020-05-07 2020-08-18 西南大学 一种真核生物CRISPR/Cas全基因组编辑载体文库及构建方法
US20230257768A1 (en) * 2020-06-12 2023-08-17 National Institute Of Advanced Industrial Science And Technology Poultry cell in which a gene encoding a protein of interest is knocked-in at egg white protein gene, and method for producing said poultry cell
CN111944847A (zh) * 2020-08-28 2020-11-17 西北农林科技大学 一套等位基因高效替换系统及其建立方法
CN113416730B (zh) * 2021-07-07 2023-04-04 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种降低细胞因基因编辑产生的大片段删除突变的方法
GB202117455D0 (en) * 2021-12-02 2022-01-19 Academisch Ziekenhuis Leiden Method of editing nucleic acid

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
JP4285766B2 (ja) 1994-03-23 2009-06-24 オハイオ ユニバーシティ 緻密にした核酸および細胞へのデリバリ
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US8772008B2 (en) * 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
US9512444B2 (en) * 2010-07-23 2016-12-06 Sigma-Aldrich Co. Llc Genome editing using targeting endonucleases and single-stranded nucleic acids
EP3274454B1 (en) 2015-03-25 2021-08-25 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
EP3274453B1 (en) * 2015-03-26 2021-01-27 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
KR102888521B1 (ko) 2015-04-06 2025-11-19 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
CA2986310A1 (en) * 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
CN105734032A (zh) * 2016-03-25 2016-07-06 扬州大学 一种山羊blg基因定点敲除修饰系统及应用
ES2962711T3 (es) 2016-12-20 2024-03-20 Bristol Myers Squibb Co Métodos para aumentar la eficacia de la reparación dirigida por homología (HDR) en el genoma celular

Also Published As

Publication number Publication date
EP3559230A1 (en) 2019-10-30
KR20190095412A (ko) 2019-08-14
JP2020510443A (ja) 2020-04-09
WO2018119060A1 (en) 2018-06-28
CN110300803B (zh) 2024-05-14
CN110300803A (zh) 2019-10-01
US20230193321A1 (en) 2023-06-22
JP2024009934A (ja) 2024-01-23
EP4286523A2 (en) 2023-12-06
ES2962711T3 (es) 2024-03-20
JP2026012785A (ja) 2026-01-27
EP4286523A3 (en) 2024-03-20
CN118460529A (zh) 2024-08-09
EP3559230B1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
JP2026012785A (ja) 細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法
US12344869B2 (en) Nucleobase editors and uses thereof
JP7326391B2 (ja) 遺伝子操作CRISPR-Cas9ヌクレアーゼ
JP6993063B2 (ja) ゲノムエンジニアリング
JP6929585B2 (ja) 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物
JP6840796B2 (ja) Dna結合ドメインと切断ドメインとを連結するための組成物
AU2018240571B2 (en) Nucleobase editors comprising nucleic acid programmable DNA binding proteins
EP2596101B1 (en) Genome editing using targeting endonucleases and single-stranded nucleic acids
JP5908725B2 (ja) 標的一本鎖開裂および標的組込みのための方法、並びに組成物
JP2022051772A (ja) Dna結合ドメインと切断ドメインとを連結するための組成物
CN116209755A (zh) 可编程核酸酶和使用方法
WO2017015101A1 (en) Methods for maximizing the efficiency of targeted gene correction
BR112017016080B1 (pt) Polinucleotídeo crispr da classe 2 único, sistema crispr da classe 2 e método in vitro de modificação de uma molécula de ácido nucleico alvo em um organismo não-humano, ou em uma célula
JP2017517250A (ja) 標的エンドヌクレアーゼを用いる哺乳類ゲノムのエピジェネティック修飾
JP7338937B2 (ja) 人工的に操作されたsc機能制御システム
CN113423831A (zh) 核酸酶介导的重复扩增
US20210403906A1 (en) Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene
JP7210028B2 (ja) 遺伝子変異導入方法
WO2024182440A2 (en) Methods and compositions for modifying nucleotide sequences
BR122019001480B1 (pt) Conjunto de dois polinucleotídeos crispr de classe 2, sistema crispr de classe 2, métodos in vitro de modificação de uma molécula de ácido nucleico alvo e para modular a transcrição de pelo menos um gene na molécula de ácido nucleico alvo

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000